{"protocolSection":{"identificationModule":{"nctId":"NCT00562484","orgStudyIdInfo":{"id":"CSLCT-USF-06-28"},"organization":{"fullName":"Seqirus","class":"INDUSTRY"},"briefTitle":"A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults","officialTitle":"A Phase IV, Randomized, Observer-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in Adults Aged ≥ 18 to < 65 Years.","acronym":"CSL's IVV"},"statusModule":{"statusVerifiedDate":"2017-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-03"},"primaryCompletionDateStruct":{"date":"2009-11","type":"ACTUAL"},"completionDateStruct":{"date":"2010-01","type":"ACTUAL"},"studyFirstSubmitDate":"2007-11-20","studyFirstSubmitQcDate":"2007-11-21","studyFirstPostDateStruct":{"date":"2007-11-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-07-08","resultsFirstSubmitQcDate":"2011-08-07","resultsFirstPostDateStruct":{"date":"2011-09-12","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-10-18","lastUpdatePostDateStruct":{"date":"2017-11-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Seqirus","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe complications following influenza infection."},"conditionsModule":{"conditions":["Influenza"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":7500,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: CSL Limited Influenza Vaccine"]},{"label":"2","type":"OTHER","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"CSL Limited Influenza Vaccine","description":"A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.","armGroupLabels":["1"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Placebo","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection","description":"Incidence of Laboratory Confirmed Influenza A/B infection was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.\n\nVaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / placebo recipient infection rate.","timeFrame":"2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009"}],"secondaryOutcomes":[{"measure":"CSL's IVV Vaccine Efficacy Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection Due to Strains Matched to Vaccine Strains","description":"Incidence of laboratory confirmed influenza A/B infection due to strains matched to vaccine strains was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.\n\nVaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / Placebo recipient infection rate.","timeFrame":"2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009"},{"measure":"Incidence of Influenza-like Illness (ILI)","description":"The criteria for the protocol defined ILI were as follows:\n\n* At least one respiratory symptom:\n* cough, sore throat or nasal congestion\n* And at least one systemic symptom:\n* fever (as defined by oral temperature ≥ 37.8°C (100.0°F), or feverishness (as defined by participant's subjective feeling of fever), chills or body aches.\n\nThe CDC ILI case definition was the occurrence of fever (100°F \\[37.8°C\\] or higher) in conjunction with either cough or sore throat.","timeFrame":"2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009"},{"measure":"Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2008","timeFrame":"21 days after study vaccination"},{"measure":"Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2009","timeFrame":"21 days after study vaccination"},{"measure":"Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2008","description":"Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer \\< 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.","timeFrame":"21 days after study vaccination"},{"measure":"Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2009","description":"Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer \\< 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.","timeFrame":"21 days after study vaccination"},{"measure":"Geometric Mean Fold Increase in HI Titer 21 Days After Study Vaccination, Year 2008","description":"Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.","timeFrame":"21 days after study vaccination"},{"measure":"Geometric Mean Fold Increase in HI Titer Rate 21 Days After Study Vaccination, Year 2009","description":"Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.","timeFrame":"21 days after study vaccination"},{"measure":"Frequency and Intensity of Local and Systemic Solicited Symptoms","description":"Adverse event grading:\n\nGrade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.\n\nGrade 2 (moderate): Discomfort was enough to cause some interference with daily activities.\n\nGrade 3 (severe): Symptoms that prevented normal, everyday activities.\n\nFever Grade 1: ≥ 37.7°C - \\< 38.0°C (≥ 99.9 - \\< 100.4°F) Grade 2: ≥ 38.0°C - \\< 39.0°C (≥ 100.4 - \\< 102.2°F) Grade 3: ≥ 39.0°C (\\> 102.2°F)","timeFrame":"5 days after study vaccination"},{"measure":"Frequency and Intensity of Unsolicited Adverse Events (UAEs)","description":"UAE grading:\n\nGrade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.\n\nGrade 2 (moderate): Discomfort was enough to cause some interference with daily activities.\n\nGrade 3 (severe): Symptoms that prevented normal, everyday activities.","timeFrame":"21 days after study vaccination"},{"measure":"Serious Adverse Events (SAEs)","description":"An SAE was any untoward medical occurrence that at any dose:\n\n* Resulted in death;\n* Was life-threatening;\n* Required an unexpected in-participant hospitalization or prolongation of existing hospitalization;\n* Resulted in persistent or significant disability / incapacity;\n* Was a congenital anomaly / birth defect; and / or\n* Was medically significant (defined as an event that did not necessarily meet any of the SAE criteria, but was judged by the treating physician to potentially jeopardize the participant or require medical intervention to prevent one of the out","timeFrame":"180 days after study vaccination"},{"measure":"New Onsets of Chronic Illness (NOCI)","description":"An NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).","timeFrame":"180 days after study vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy males and females aged ≥ 18 to \\< 65 years at the time of vaccination\n* Non pregnant/ non lactating females\n\nExclusion Criteria:\n\n* Hypersensitivity to influenza vaccine or allergy to any components of the Study Vaccines\n* Vaccination against influenza in the previous 6 months\n* Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality\n* Known history of Guillain-Barré Syndrome;\n* Clinical signs of active infection and/or an oral temperature of ≥ 37.8 oC.\n* History of neurological disorders or seizures\n* Confirmed or suspected immunosuppressive condition or a previously diagnosed immunodeficiency disorder\n* Current or recent immunosuppressive or immunomodulative therapy, including systemic corticosteroids\n* Administration of immunoglobulins and/or any blood products;\n* Participation in a clinical trial or use of an investigational compound;\n* Vaccination with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior;\n* Participants indicated to receive an influenza vaccine on an annual basis according to the local public health recommendations.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Director Vaccines","affiliation":"Seqirus","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"The Clinical Trials Unit, Canberra Hospital","city":"Canberra","state":"Australian Capital Territory","country":"Australia","geoPoint":{"lat":-35.28346,"lon":149.12807}},{"facility":"Australian Clinical Research Organisation","city":"Brookvale","state":"New South Wales","country":"Australia","geoPoint":{"lat":-33.76108,"lon":151.27446}},{"facility":"Australian Clinical Research Organisation","city":"Caringbah","state":"New South Wales","country":"Australia","geoPoint":{"lat":-34.03534,"lon":151.12468}},{"facility":"Eastern Area Health Service, Prince of Wales Hospital","city":"Randwick","state":"New South Wales","country":"Australia","geoPoint":{"lat":-33.91439,"lon":151.24895}},{"facility":"National Centre for Immunisation Research & Surveillance (NCIRS) The Children's Hospital at Westmead","city":"Westmead","state":"New South Wales","country":"Australia","geoPoint":{"lat":-33.80383,"lon":150.98768}},{"facility":"Australian Clinical Research Organisation","city":"Auchenflower","state":"Queensland","zip":"4066","country":"Australia","geoPoint":{"lat":-27.47443,"lon":152.99213}},{"facility":"Trialworks Clinical Research Services","city":"Brisbane","state":"Queensland","country":"Australia","geoPoint":{"lat":-27.46794,"lon":153.02809}},{"facility":"Australian Clinical Research Organisation Caboolture Clinical Research Centre","city":"Caboolture","state":"Queensland","zip":"4510","country":"Australia","geoPoint":{"lat":-27.08465,"lon":152.9511}},{"facility":"School of Medicine, James Cook University, Cairns Base Hospital","city":"Cairns","state":"Queensland","country":"Australia","geoPoint":{"lat":-16.92366,"lon":145.76613}},{"facility":"Gold Coast Hospital","city":"Gold Coast","state":"Queensland","country":"Australia","geoPoint":{"lat":-28.00029,"lon":153.43088}},{"facility":"Australian Clinical Research Organisation","city":"Kippa-Ring","state":"Queensland","country":"Australia","geoPoint":{"lat":-27.22586,"lon":153.0835}},{"facility":"CMAX, a division of IDT Australia","city":"Adelaide","state":"South Australia","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Paediatric Trials Unit, Women's and Children's Hospital","city":"Adelaide","state":"South Australia","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Primary Old Port Road Medical and Dental Centre","city":"Royal Park","state":"South Australia","zip":"5014","country":"Australia","geoPoint":{"lat":-34.87415,"lon":138.51189}},{"facility":"Sexual Health Service","city":"Hobart","state":"Tasmania","country":"Australia","geoPoint":{"lat":-42.87936,"lon":147.32941}},{"facility":"Barwon Health, Geelong Hospital","city":"Geelong","state":"Victoria","country":"Australia","geoPoint":{"lat":-38.14711,"lon":144.36069}},{"facility":"Emeritus Research","city":"Malvern East","state":"Victoria","country":"Australia","geoPoint":{"lat":-37.87397,"lon":145.04253}},{"facility":"Murdoch Childrens Research Institute","city":"Melbourne","state":"Victoria","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Lung Institute of Western Australia","city":"Perth","state":"Western Australia","country":"Australia","geoPoint":{"lat":-31.95224,"lon":115.8614}},{"facility":"Princess Margaret Hospital for Children","city":"Perth","state":"Western Australia","country":"Australia","geoPoint":{"lat":-31.95224,"lon":115.8614}},{"facility":"Auckland Clinical Studies","city":"Auckland","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"198 Youth Health Centre","city":"Christchurch","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}},{"facility":"Southern Clinical Trials","city":"Christchurch","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}},{"facility":"RMC Medical Centre","city":"Dunedin","country":"New Zealand","geoPoint":{"lat":-45.87416,"lon":170.50361}}]},"referencesModule":{"references":[{"pmid":"27595443","type":"DERIVED","citation":"Mcbride WJH, Abhayaratna WP, Barr I, Booy R, Carapetis J, Carson S, De Looze F, Ellis-Pegler R, Heron L, Karrasch J, Marshall H, Mcvernon J, Nolan T, Rawlinson W, Reid J, Richmond P, Shakib S, Basser RL, Hartel GF, Lai MH, Rockman S, Greenberg ME. Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial. Vaccine. 2016 Sep 22;34(41):4991-4997. doi: 10.1016/j.vaccine.2016.08.038. Epub 2016 Aug 29."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"FG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10033"},{"groupId":"FG001","numSubjects":"5011"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9827"},{"groupId":"FG001","numSubjects":"4907"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"104"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"Moved away from the study area","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"132"},{"groupId":"FG001","numSubjects":"71"}]},{"type":"Reason not provided or not specified","reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"12"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"BG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10033"},{"groupId":"BG001","value":"5011"},{"groupId":"BG002","value":"15044"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"10033"},{"groupId":"BG001","value":"5011"},{"groupId":"BG002","value":"15044"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35.5","spread":"14.69"},{"groupId":"BG001","value":"35.4","spread":"14.69"},{"groupId":"BG002","value":"35.5","spread":"14.69"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5523"},{"groupId":"BG001","value":"2667"},{"groupId":"BG002","value":"8190"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4510"},{"groupId":"BG001","value":"2344"},{"groupId":"BG002","value":"6854"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"8201"},{"groupId":"BG001","value":"4090"},{"groupId":"BG002","value":"12291"}]}]},{"title":"New Zealand","categories":[{"measurements":[{"groupId":"BG000","value":"1832"},{"groupId":"BG001","value":"921"},{"groupId":"BG002","value":"2753"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection","description":"Incidence of Laboratory Confirmed Influenza A/B infection was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.\n\nVaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / placebo recipient infection rate.","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9889"},{"groupId":"OG001","value":"4960"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","lowerLimit":"1.97","upperLimit":"2.57"},{"groupId":"OG001","value":"3.87","lowerLimit":"3.37","upperLimit":"4.44"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy = 100 x (1 - ratio of incidence rate)","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Vaccine Efficacy","paramValue":"42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"30","ciUpperLimit":"52"}]},{"type":"SECONDARY","title":"CSL's IVV Vaccine Efficacy Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection Due to Strains Matched to Vaccine Strains","description":"Incidence of laboratory confirmed influenza A/B infection due to strains matched to vaccine strains was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.\n\nVaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / Placebo recipient infection rate.","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9889"},{"groupId":"OG001","value":"4960"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","lowerLimit":"0.45","upperLimit":"0.76"},{"groupId":"OG001","value":"1.47","lowerLimit":"1.17","upperLimit":"1.85"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Vaccine efficacy = 100 x (1 - ratio of incidence rate)","nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Vaccine efficacy","paramValue":"60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"44","ciUpperLimit":"72"}]},{"type":"SECONDARY","title":"Incidence of Influenza-like Illness (ILI)","description":"The criteria for the protocol defined ILI were as follows:\n\n* At least one respiratory symptom:\n* cough, sore throat or nasal congestion\n* And at least one systemic symptom:\n* fever (as defined by oral temperature ≥ 37.8°C (100.0°F), or feverishness (as defined by participant's subjective feeling of fever), chills or body aches.\n\nThe CDC ILI case definition was the occurrence of fever (100°F \\[37.8°C\\] or higher) in conjunction with either cough or sore throat.","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9889"},{"groupId":"OG001","value":"4960"}]}],"classes":[{"title":"Reported ILI (protocol definition)","categories":[{"measurements":[{"groupId":"OG000","value":"11.9"},{"groupId":"OG001","value":"13.5"}]}]},{"title":"Culture-confirmed ILI","categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"2.4"}]}]},{"title":"Reported ILI (CDC definition)","categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"3.6"}]}]},{"title":"Laboratory-confirmed ILI (CDC definition)","categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"1.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2008","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"21 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"147"}]}],"classes":[{"title":"H1N1 (A/Solomon Islands/3/2006)","categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"97","upperLimit":"100"},{"groupId":"OG001","value":"42","lowerLimit":"34","upperLimit":"51"}]}]},{"title":"H3N2 (A/Brisbane/10/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"94","upperLimit":"98"},{"groupId":"OG001","value":"35","lowerLimit":"27","upperLimit":"43"}]}]},{"title":"B (B/Brisbane/3/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"77","lowerLimit":"72","upperLimit":"82"},{"groupId":"OG001","value":"13","lowerLimit":"8","upperLimit":"19"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2009","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"21 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"H1N1 (A/Brisbane/59/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"90","upperLimit":"96"},{"groupId":"OG001","value":"36","lowerLimit":"28","upperLimit":"44"}]}]},{"title":"H3N2 (A/Uruguay/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"90","upperLimit":"96"},{"groupId":"OG001","value":"43","lowerLimit":"35","upperLimit":"51"}]}]},{"title":"B (B/Florida/4/2006)","categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"85","upperLimit":"93"},{"groupId":"OG001","value":"30","lowerLimit":"23","upperLimit":"38"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2008","description":"Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer \\< 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"21 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"147"}]}],"classes":[{"title":"H1N1 (A/Solomon Islands/3/2006)","categories":[{"measurements":[{"groupId":"OG000","value":"81","lowerLimit":"76","upperLimit":"85"},{"groupId":"OG001","value":"1","lowerLimit":"0","upperLimit":"4"}]}]},{"title":"H3N2 (A/Brisbane/10/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"87","lowerLimit":"82","upperLimit":"90"},{"groupId":"OG001","value":"1","lowerLimit":"0","upperLimit":"4"}]}]},{"title":"B (B/Brisbane/3/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"63","lowerLimit":"57","upperLimit":"69"},{"groupId":"OG001","value":"1","lowerLimit":"0","upperLimit":"4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2009","description":"Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer \\< 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"21 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"H1N1 (A/Brisbane/59/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"78","lowerLimit":"72","upperLimit":"82"},{"groupId":"OG001","value":"1","lowerLimit":"0","upperLimit":"4"}]}]},{"title":"H3N2 (A/Uruguay/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"81","lowerLimit":"76","upperLimit":"85"},{"groupId":"OG001","value":"1","lowerLimit":"0","upperLimit":"5"}]}]},{"title":"B (B/Florida/4/2006)","categories":[{"measurements":[{"groupId":"OG000","value":"61","lowerLimit":"55","upperLimit":"67"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Increase in HI Titer 21 Days After Study Vaccination, Year 2008","description":"Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold increase","timeFrame":"21 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"147"}]}],"classes":[{"title":"H1N1 (A/Solomon Islands/3/2006)","categories":[{"measurements":[{"groupId":"OG000","value":"21","lowerLimit":"17","upperLimit":"26"},{"groupId":"OG001","value":"1","lowerLimit":"1","upperLimit":"1"}]}]},{"title":"H3N2 (A/Brisbane/10/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"18","lowerLimit":"15","upperLimit":"21"},{"groupId":"OG001","value":"1","lowerLimit":"1","upperLimit":"1"}]}]},{"title":"B (B/Brisbane/3/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"8","lowerLimit":"7","upperLimit":"10"},{"groupId":"OG001","value":"1","lowerLimit":"1","upperLimit":"1"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Increase in HI Titer Rate 21 Days After Study Vaccination, Year 2009","description":"Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.","populationDescription":"Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold increase","timeFrame":"21 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"H1N1 (A/Brisbane/59/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"13","lowerLimit":"11","upperLimit":"16"},{"groupId":"OG001","value":"1","lowerLimit":"1","upperLimit":"1"}]}]},{"title":"H3N2 (A/Uruguay/2007)","categories":[{"measurements":[{"groupId":"OG000","value":"15","lowerLimit":"13","upperLimit":"18"},{"groupId":"OG001","value":"1","lowerLimit":"1","upperLimit":"1"}]}]},{"title":"B (B/Florida/4/2006)","categories":[{"measurements":[{"groupId":"OG000","value":"6","lowerLimit":"5","upperLimit":"7"},{"groupId":"OG001","value":"1","lowerLimit":"1","upperLimit":"1"}]}]}]},{"type":"SECONDARY","title":"Frequency and Intensity of Local and Systemic Solicited Symptoms","description":"Adverse event grading:\n\nGrade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.\n\nGrade 2 (moderate): Discomfort was enough to cause some interference with daily activities.\n\nGrade 3 (severe): Symptoms that prevented normal, everyday activities.\n\nFever Grade 1: ≥ 37.7°C - \\< 38.0°C (≥ 99.9 - \\< 100.4°F) Grade 2: ≥ 38.0°C - \\< 39.0°C (≥ 100.4 - \\< 102.2°F) Grade 3: ≥ 39.0°C (\\> 102.2°F)","populationDescription":"Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"5 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10015"},{"groupId":"OG001","value":"5005"}]}],"classes":[{"title":"Any local solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"7474"},{"groupId":"OG001","value":"1021"}]}]},{"title":"Any pain","categories":[{"measurements":[{"groupId":"OG000","value":"4850"},{"groupId":"OG001","value":"539"}]}]},{"title":"Grade 3 pain","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"6956"},{"groupId":"OG001","value":"874"}]}]},{"title":"Grade 3 tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"2"}]}]},{"title":"Any redness","categories":[{"measurements":[{"groupId":"OG000","value":"362"},{"groupId":"OG001","value":"18"}]}]},{"title":"Grade 3 redness","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any swelling / induration","categories":[{"measurements":[{"groupId":"OG000","value":"433"},{"groupId":"OG001","value":"20"}]}]},{"title":"Grade 3 swelling / induration","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any bruising","categories":[{"measurements":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"29"}]}]},{"title":"Grade 3 bruising","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Any systemic solicited symptom","categories":[{"measurements":[{"groupId":"OG000","value":"4670"},{"groupId":"OG001","value":"1955"}]}]},{"title":"Any fever","categories":[{"measurements":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"93"}]}]},{"title":"Grade 3 fever","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"}]}]},{"title":"Any headache","categories":[{"measurements":[{"groupId":"OG000","value":"2553"},{"groupId":"OG001","value":"1176"}]}]},{"title":"Grade 3 headache","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"19"}]}]},{"title":"Any malaise","categories":[{"measurements":[{"groupId":"OG000","value":"2916"},{"groupId":"OG001","value":"1277"}]}]},{"title":"Grade 3 malaise","categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"24"}]}]},{"title":"Any myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"2150"},{"groupId":"OG001","value":"609"}]}]},{"title":"Grade 3 myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"5"}]}]},{"title":"Any chills","categories":[{"measurements":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"187"}]}]},{"title":"Grade 3 chills","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"3"}]}]},{"title":"Any nausea","categories":[{"measurements":[{"groupId":"OG000","value":"678"},{"groupId":"OG001","value":"287"}]}]},{"title":"Grade 3 nausea","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}]}]},{"title":"Any vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"38"}]}]},{"title":"Grade 3 vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Frequency and Intensity of Unsolicited Adverse Events (UAEs)","description":"UAE grading:\n\nGrade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.\n\nGrade 2 (moderate): Discomfort was enough to cause some interference with daily activities.\n\nGrade 3 (severe): Symptoms that prevented normal, everyday activities.","populationDescription":"Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"21 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9889"},{"groupId":"OG001","value":"4960"}]}],"classes":[{"title":"Number of participants with at least one UAE","categories":[{"measurements":[{"groupId":"OG000","value":"3519"},{"groupId":"OG001","value":"1698"}]}]},{"title":"Number of participants reported Grade 1 UAE","categories":[{"measurements":[{"groupId":"OG000","value":"1604"},{"groupId":"OG001","value":"750"}]}]},{"title":"Number of participants reported Grade 2 UAE","categories":[{"measurements":[{"groupId":"OG000","value":"1536"},{"groupId":"OG001","value":"784"}]}]},{"title":"Number of participants reported Grade 3 UAE","categories":[{"measurements":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"162"}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Events (SAEs)","description":"An SAE was any untoward medical occurrence that at any dose:\n\n* Resulted in death;\n* Was life-threatening;\n* Required an unexpected in-participant hospitalization or prolongation of existing hospitalization;\n* Resulted in persistent or significant disability / incapacity;\n* Was a congenital anomaly / birth defect; and / or\n* Was medically significant (defined as an event that did not necessarily meet any of the SAE criteria, but was judged by the treating physician to potentially jeopardize the participant or require medical intervention to prevent one of the out","populationDescription":"Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"180 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9889"},{"groupId":"OG001","value":"4960"}]}],"classes":[{"title":"Number of participants with at least one SAE","categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"44"}]}]},{"title":"Number rof participants with related SAE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"New Onsets of Chronic Illness (NOCI)","description":"An NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).","populationDescription":"Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"180 days after study vaccination","groups":[{"id":"OG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV"},{"id":"OG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9889"},{"groupId":"OG001","value":"4960"}]}],"classes":[{"title":"Number of participants with at least one NOCI","categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"46"}]}]},{"title":"Number of participants with related NOCI","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"21 days after study vaccination for unsolicited adverse events and 180 days after study vaccination for serious adverse events.","description":"Other adverse events presented were unsolicited adverse events up to 21 days after study vaccination","eventGroups":[{"id":"EG000","title":"CSL's IVV","description":"Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV","seriousNumAffected":100,"seriousNumAtRisk":10015,"otherNumAffected":3028,"otherNumAtRisk":10015},{"id":"EG001","title":"Placebo","description":"Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season","seriousNumAffected":44,"seriousNumAtRisk":5005,"otherNumAffected":1549,"otherNumAtRisk":5005}],"seriousEvents":[{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":10015},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":5005}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":10015},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":5005}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10015},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":5005}]},{"term":"Vestibular neuronitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Bacterial pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Bartholin's abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Cellulitis of male external genital organ","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Haemophilus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Herpes simplex hepatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Liver abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Measles","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Peritonsillar abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Pyomyositis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"B precursor type acute leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Breast cancer in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Colon cancer stage II","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Leiomyosarcoma metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Non-Hodgkin's lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Ovarian adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Throat cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Uterine leiomyoma","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Amyloidosis","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Major depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"cervical myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Aortic valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Sick sinus syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Tracheal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":5005}]},{"term":"Crohn's disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Abdominal hernia obstructive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Ileitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Intussusception","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Pancreatitis relapsing","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Reflux oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Umbilical hernia obstructive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Uvulitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Cholecystitis chronic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Fracture nonunion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Acute prerenal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Focal segmental glomerulosclerosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Renal cyst ruptured","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Ruptured ectopic pregnancy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Cervical polyp","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Endometriosis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Haemorrhagic ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Ovarian cyst ruptured","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Vaginal prolapse","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Bicuspid aortic valve","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Heart disease congenital","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Trisomy 21","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":5005}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Ligament rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Anaesthetic complication pulmonary","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Facial bones fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Incisional hernia","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Jaw fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Multiple injuries","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Pubic rami fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]},{"term":"Subdural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Borderline ovarian tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Ovarian cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":5005}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10015},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":5005}]},{"term":"Heart injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10015},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":5005}]}],"otherEvents":[{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":402,"numAffected":387,"numAtRisk":10015},{"groupId":"EG001","numEvents":205,"numAffected":201,"numAtRisk":5005}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1567,"numAffected":1128,"numAtRisk":10015},{"groupId":"EG001","numEvents":712,"numAffected":558,"numAtRisk":5005}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":529,"numAffected":501,"numAtRisk":10015},{"groupId":"EG001","numEvents":276,"numAffected":258,"numAtRisk":5005}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":273,"numAffected":248,"numAtRisk":10015},{"groupId":"EG001","numEvents":160,"numAffected":150,"numAtRisk":5005}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":228,"numAffected":220,"numAtRisk":10015},{"groupId":"EG001","numEvents":112,"numAffected":104,"numAtRisk":5005}]},{"term":"Rhinorrhea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":163,"numAffected":155,"numAtRisk":10015},{"groupId":"EG001","numEvents":82,"numAffected":80,"numAtRisk":5005}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":155,"numAffected":135,"numAtRisk":10015},{"groupId":"EG001","numEvents":78,"numAffected":70,"numAtRisk":5005}]},{"term":"Dysmenorrhea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":148,"numAffected":144,"numAtRisk":10015},{"groupId":"EG001","numEvents":77,"numAffected":73,"numAtRisk":5005}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":113,"numAffected":110,"numAtRisk":10015},{"groupId":"EG001","numEvents":56,"numAffected":55,"numAtRisk":5005}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Clinical Study Disclosure Manager","organization":"Seqirus","email":"Seqirus.ClinicalTrials@Seqirus.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}